Thyroid remnant radioiodine ablation with recombinant human thyrotropin

R. Michael Tuttle, Richard J. Robbins

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The primary treatment modalities for most patients with differentiated thyroid cancer include total thyroidectomy and radioactive iodine (RAI) remnant ablation (RRA; 1). The goal of RRA is to eliminate not only normal thyroid cells but also to destroy any residual microscopic thyroid carcinoma that may remain following total thyroidectomy and appropriate lymph node dissection. As reviewed in Chapters 14, 26, 32, and 88, RAI uptake into thyroid cells is enhanced by a lowiodine diet and thyrotropin (TSH) stimulation. For the past 40-50 yr, endogenous TSH production was stimulated by several weeks of thyroid hormone withdrawal prior to RAI dosing. However, thyroid hormone withdrawal often results in hypothyroid symptoms that are not well tolerated by many patients.

Original languageEnglish (US)
Title of host publicationThyroid Cancer (Second Edition)
Subtitle of host publicationA Comprehensive Guide to Clinical Management
PublisherHumana Press
Pages283-286
Number of pages4
ISBN (Print)9781588294623
DOIs
StatePublished - Dec 1 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Thyroid remnant radioiodine ablation with recombinant human thyrotropin'. Together they form a unique fingerprint.

Cite this